Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 3/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253601 | 0.77 | HTR1D (0.89) | HTR1DNOS3NOS1NOS2 | |
| SCHEMBL7253426 | 0.76 | HTR1D (0.79) | HTR1DNOS3NOS1 | |
| SCHEMBL7252919 | 0.69 | HTR1D (0.42) | HTR1DMTNR1AMTNR1BNOS3NOS1 | |
| SCHEMBL7253516 | 0.65 | HTR1D (0.77) | HTR1DNOS3NOS1NOS2 | |
| SCHEMBL7252909 | 0.65 | HTR1D (0.61) | HTR1DNOS3NOS1NOS2 | |
| SCHEMBL7253548 | 0.64 | HTR1D (0.68) | HTR1DNOS3NOS1 | |
| SCHEMBL7253250 | 0.64 | HTR1D (1.00) | HTR1DNOS3NOS1NOS2 | |
| SCHEMBL26673423 | 0.64 | HTR1D (0.52) | HTR1DSMN1; SMN2HSD17B10 | |
| SCHEMBL7253280 | 0.62 | HTR1D (0.36) | HTR1D | |
| SCHEMBL2265401 | 0.57 | NOS3 (0.48) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
| EP-1140074-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038677-A1 | INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR1D 128/4885MTNR1A 288/4885MTNR1B 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.